Aesthetic Medical International Holdings Group Limited, founded in Shenzhen, China in 1997, is an international listed group specialized in aesthetic medical services as well as the first aesthetic medical services organization listed in China's main board. AIH has always prioritized the safety and quality of aesthetic services, making it one of aesthetic services institutions with the best medical safety records as well as with the longest history in the industry and thus enjoying prestige in the society and among consumers.
Company profile
Ticker
PAIYY
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
PAIYY stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
16 Aug 24
25-NSE
Exchange delisting
19 Jul 24
6-K
Aesthetic Medical International Holdings Group Ltd. Announces the Commencement of OTCQX Trading
10 Jul 24
6-K
Aesthetic Medical International Holdings Group Ltd. Announces Receipt of Delisting Decision from the Nasdaq Hearings Panel
20 May 24
6-K
Aesthetic Medical International Holdings Group Ltd. Announces Receipt of Decision from the Nasdaq Hearings Panel for Conditional Continued Listing
25 Apr 24
20-F
2023 FY
Annual report (foreign)
25 Apr 24
6-K
Current report (foreign)
8 Mar 24
6-K
Aesthetic Medical International Announces Change of Auditor and Change of Director
12 Dec 23
UPLOAD
Letter from SEC
16 Oct 23
20-F/A
2022 FY
Annual report (foreign) (amended)
22 Sep 23
Transcripts
PAIYY
Earnings call transcript
2023 Q1
17 May 23
PAIYY
Earnings call transcript
2023 Q1
21 Apr 23
PAIYY
Earnings call transcript
2022 Q3
29 Nov 22
PAIYY
Earnings call transcript
2022 Q2
17 Aug 22
PAIYY
Earnings call transcript
2021 Q2
16 Nov 21
PAIYY
Earnings call transcript
2021 Q1
24 Jun 21
PAIYY
Earnings call transcript
2020 Q4
20 Apr 21
PAIYY
Earnings call transcript
2020 Q3
30 Nov 20
Latest ownership filings
SC 13D/A
Peak Asia Investment Holdings V Ltd
17 Aug 23
SC 13D/A
Hainan Oriental Jiechuang Investment Partnership (Limited Partnership)
17 Aug 23
SC 13D/A
Hainan Oriental Jiechuang Investment Partnership (Limited Partnership)
24 Feb 23
SC 13D/A
Peak Asia Investment Holdings V Ltd
29 Jul 22
SC 13D
Hainan Oriental Jiechuang Investment Partnership (Limited Partnership)
29 Jul 22
SC 13D
Zhou Pengwu
29 Jul 22
SC 13D
Ding Wenting
29 Jul 22
SC 13D/A
Hainan Runming Biotechnology Co., Ltd.
14 Jul 22
SC 13D
Hainan Runming Biotechnology Co., Ltd.
10 Jun 22
SC 13G/A
IDG-Accel China Growth Fund III L.P.
28 Feb 22
Financial summary
Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 1 |
Closed positions | 3 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 706.96 mm |
Total shares | 159.49 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Hainan Oriental Jiechuang Investment Partnership | 88.10 mm | $122.90 mm |
Hainan Runming Biotechnology | 21.41 mm | $48.61 mm |
Zhou Pengwu | 16.12 mm | $33.08 mm |
Peak Asia Investment Holdings V | 15.58 mm | $31.96 mm |
Ding Wenting | 15.49 mm | $31.79 mm |
IDG-Accel China Growth Fund III | 2.38 mm | $8.27 mm |
IDG Technology Venture Investment IV | 396.09 k | $415.89 mm |
Rhumbline Advisers | 12.00 k | $12.35 mm |
Nordwand Advisors | 2.00 k | $2.10 mm |
Proequities | 0.00 | $0.00 |